3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.

Roxana Mehran,Davide Cao,Dominick J. Angiolillo,Sripal Bangalore,Deepak L. Bhatt,Junbo Ge,James B. Hermiller,Raj Makkar,Franz-Josef Neumann,Shigeru Saito,Héctor Picón,Ralph Toelg,Aziz Maksoud,Bassem M. Chehab,José M. de la Torre Hernández,Vijay Kunadian,Gennaro Sardella,Holger Thiele,Olivier Varenne,Pascal Vranckx,Stephan Windecker,Yujie Zhou,Mitchell W. Krucoff,Karine Ruster,Jin Wang,Marco Valgimigli,Xience,Xience Investigators

3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation.

2021

Abstract Objectives The aim of this study was to evaluate 2 abbreviated dual-antiplatelet therapy (DAPT) regimens in patients at high bleeding risk (HBR) undergoing percutaneous coronary interventi...

Keywords:

everolimus eluting stent
in patient
Surgery
Thrombosis
Percutaneous coronary intervention
Percutaneous
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations